Senti Biosciences, Inc. (SNTI) AI Stock Analysis

Senti Biosciences, Inc. is a preclinical biotechnology company founded in 2016 and based in South San Francisco, California, with 39 employees. The company focuses on developing next-generation cell and gene therapies using its proprietary gene circuit platform technologies. Its product pipeline centers on allogeneic chimeric antigen receptor natural killer (CAR-NK) cell therapies for oncology indications. Leading candidates include SENTI-202, an off-the-shelf therapy targeting acute myeloid leukemia while sparing healthy bone marrow, SENTI-301 for hepatocellular carcinoma, and SENTI-401 for colorectal cancer.

Revenue has fluctuated sharply, rising 363.5% to $394,000 in FY2020 and reaching $4.3M in FY2022 before contracting 53.8% to $2.0M in FY2023. In FY2025, revenue fell 98.9% to $22,000, with gross margin dropping to -16431.8% and operating margin reaching -289668.2%. The net loss for FY2025 was -$61.4M, driven by $37.6M in research and development expenses. Over the 5-year period through FY2025, revenue contracted at a CAGR of -23.7%. For the trailing twelve months ended June 30, 2026, revenue totaled $55,000, with diluted EPS of -$1.72 and quarterly revenue down 100.0% year-over-year.

As of June 30, 2026, Senti Biosciences held $6.5M in cash and short-term investments, total debt of $20.2M, and net debt of $13.8M. Total assets stood at $33.1M against negative shareholders' equity of -$3.4M, with a current ratio of 0.83. Operating cash flow in FY2025 was -$43.4M, and free cash flow was -$43.6M after capital expenditures of $196,000. Over a 5-year period, the company's share count increased by 613.4%.

With a market capitalization of $7.0M and an enterprise value of $24.4M, SNTI trades at a price-to-sales multiple of 127.4x and an EV to revenue multiple of 442.8x. These multiples stand well above the median of its US-listed Healthcare peers, which has a price-to-sales multiple of 4.1x. The stock trades at a price-to-book ratio of 5.5x. Over the past year, SNTI shares fell 89.7% while the S&P 500 (SPY) gained 16.8%, and over five years the stock fell 99.8% compared to an 83.0% rise for the benchmark.

Covering analysts have posted 1 Strong Buy and 1 Buy rating, with no Hold or Sell recommendations. The consensus mean price target is $13.50, compared to the last close of $0.23 on October 16, 2026, implying 5900.0% potential upside. For the fiscal year ending December 31, 2026, analysts estimate revenue of $50,000 and EPS of -$1.04. Senti Biosciences beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 12, 2026.

This page is an AI-written research summary of Senti Biosciences, Inc. (SNTI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SNTI income statement, SNTI balance sheet, SNTI key metrics, SNTI analyst forecast, SNTI chart. See the SNTI stock overview for the latest quote and news.